KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBT Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBT Margin readings, the most recent being 35030.65% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 3505041.0% to 35030.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 57.01%, a 7631.0% increase, with the full-year FY2025 number at 30.56%, up 4986.0% from a year prior.
  • EBT Margin hit 35030.65% in Q4 2025 for Biocryst Pharmaceuticals, up from 7.61% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 35030.65% in Q4 2025 to a low of 337.29% in Q1 2021.
  • Median EBT Margin over the past 5 years was 47.68% (2022), compared with a mean of 1685.29%.
  • Biggest five-year swings in EBT Margin: plummeted -5692bps in 2022 and later surged 3505041bps in 2025.
  • Biocryst Pharmaceuticals' EBT Margin stood at 32.92% in 2021, then crashed by -173bps to 89.84% in 2022, then increased by 25bps to 67.62% in 2023, then surged by 71bps to 19.76% in 2024, then soared by 177381bps to 35030.65% in 2025.
  • The last three reported values for EBT Margin were 35030.65% (Q4 2025), 7.61% (Q3 2025), and 3.97% (Q2 2025) per Business Quant data.